Regnault C, Soursac M, Roch-Arveiller M, Postaire E, Hazebroucq G. Pharmacokinetics of superoxide dismutase in rats after oral administration.
Biopharm Drug Dispos. 1996;17:165–74.
Giri SN, Misra HP. Fate of superoxide dismutase in mice following oral route of administration.
Med Biol. 1984;62:285–9.
Regnault C, Roch-Arveiller M, Tissot M, et al.
Effect of encapsulation on the anti-inflammatory properties of superoxide dismutase after oral administration.
Clin Chim Acta. 1995;240:117–27.
Delanian S, Martin M, Bravard A, Luccioni C, Lefaix JL. Cu/Zn superoxide dismutase modulates phenotypic changes in cultured fibroblasts from human skin with chronic radiotherapy damage.
Radiother Oncol. 2001;58:325–31.
Delanian S, Baillet F, Huart J, Lefaix JL, Maulard C, Housset M. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial.
Radiother Oncol. 1994;32:12–20.
Housset M, Baillet F, Michelson AM, Puget K. Action of liposomal superoxide dismutase on measurable radiation-induced fibrosis.
Ann Med Interne (Paris). 1989;140:365–7.
Lefaix JL, Delanian S, Leplat JJ, et al.
Radiation-induced cutaneo-muscular fibrosis (III): major therapeutic efficacy of liposomal Cu/Zn superoxide dismutase [in French].
Bull Cancer. 1993;80:799–807.
Ratcheva I, Stefanova Z, Vesselinova A, Nikolova S, Kujumdjieva A, Neychev H. Treatment of adjuvant arthritis in mice with yeast superoxide dismutase.
Vorauer-Uhl K, Furnschlief E, Wagner A, et al. Reepithelialization of experimental scalds effected by topically applied superoxide dismutase: controlled animal studies.
Wound Repair Regen. 2002;10:366–71.
Flanagan SW, Anderson RD, Ross MA, Oberley LW.
Overexpression of manganese superoxide dismutase attenuates neuronal death in human cells expressing mutant (G37R) Cu/Zn-superoxide dismutase.
J Neurochem. 2002;81:170–7.
Gallagher IM, Jenner P, Glover V, Clow A. CuZn-superoxide dismutase transgenic mice: no effect on longevity, locomotor activity and 3H-mazindol and 3H-spiperone binding over 19 months.
Neurosci Lett. 2000;289:221–3.
Huang TT, Carlson EJ, Gillespie AM, Shi Y, Epstein CJ. Ubiquitous overexpression of CuZn superoxide dismutase does not extend life span in mice.
J Gerontol A Biol Sci Med Sci. 2000;55:B5–9.
Parkes TL, Elia AJ, Dickinson D, Hilliker AJ, Phillips JP, Boulianne GL. OMIM
lifespan by overexpression of human SOD1 in motorneurons.
Nat Genet. 1998;19:171–4.
Davis JM, Rosenfeld WN, Richter SE, et al. The effects of multiple doses of recombinant human CuZn superoxide dismutase (rhSOD) in premature infants with respiratory distress syndrome (RDS).
Pediatr Res. 1999;45:193A (Abstract no.1129).
Davis JM, Richter SE, Biswas S, et al. Long-term follow-up of premature infants treated with prophylactic, intratracheal recombinant human CuZn superoxide dismutase.
J Perinatol. 2000;4:213–216.
Rosenfeld WN, Davis JM, Parton L, et al. Safety and pharmacokinetics of recombinant human superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.